MedPath

EPIGENETIX, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Castrate Resistant Prostate Cancer
NUT Carcinoma
Chronic Myelomonocytic Leukemia
Myelofibrosis
Interventions
First Posted Date
2022-08-04
Last Posted Date
2025-01-14
Lead Sponsor
Epigenetix, Inc.
Target Recruit Count
50
Registration Number
NCT05488548
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.